Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study.
Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study.
复制标题
动脉内输注卡铂治疗恶性神经胶质瘤：一项 II 期研究。
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
J. Chiras
中科院分区：
文献类型：
--
作者：
J. Follezou;F. Fauchon;J. Chiras
23例既往接受过治疗的恶性胶质瘤患者被纳入这项卡铂（400 mg/m2）每4周一次动脉内输注给药的II期研究。5例患者（19例可评价患者中的26%）在3至10个月内达到部分缓解，5例患者在2至7个月内保持稳定。大多数患者的毒性轻微，恶心、呕吐和骨髓抑制是最常见的副作用。未观察到肾脏或听觉毒性。一名患者出现中枢神经毒性，另一名患者出现视力可逆性下降。最后，卡铂动脉灌注似乎是一种活性药物，毒性低于顺铂，在恶性胶质瘤，并需要进一步的试验。
Twenty-three previously treated patients with malignant gliomas were included in this phase II study of carboplatin (400 mg/m2) given as an intraarterial infusion every 4 weeks. Five patients (26% of 19 evaluable) achieved a partial response for 3 to 10 months and 5 patients presented a stabilization for 2 to 7 months. Toxicity was mild in most patients, with nausea, vomiting and myelosuppression being the most frequent side-effects. No renal or auditory toxicity was observed. One patient developed central nervous toxicity and another one a reversible fall in visual acuity. Finally, carboplatin infused by the intraarterial route seems to be an active drug, less toxic than cisplatin, in malignant gliomas, and further trials are warranted.